Dossier
TRANSCEND-T2D-1
Coverage of TRANSCEND-T2D-1 in the Nexus archive.
- Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
Monotherapy with once-weekly retatrutide, an investigational triple hormone receptor agonist, improved glycemic control and body weight in adults with type 2 diabetes, as shown in the phase III TRANSCEND-T2D-1 trial. Up to 40% of patients achieved normal HbA1c levels.
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant weight loss and blood sugar reduction in a study, but new data revealed seven cases of arrhythmias and three major cardiovascular complications among 403 participants. The findings were presented at the American Diabetes Association meeting and published in the Lancet.